Development of a liquid tumor potency assay for evaluation of immune cell-mediated cytotoxicity in vitro

Abstract The development of immunotherapies relies on the use in vitro potency assays—which are key for understanding complex interactions between immune (effector) cells and cancer (target) cells—to evaluate function, specificity, sensitivity a product. A variety assays used to characterize proliferation, cytokine release, cell-mediated cytotoxicity engineered cells, such as chimeric antigen receptor (CAR) T with each representing an important aspect driving clinical efficacy cellular Previous work has shown that impedance-based provide real-time, label-free measure effector adherent target cells. Here, we describe assay quantifies liquid tumor First, wells were coated antibody tether (Raji = anti-CD40, K562 anti-CD71, Daudi anti-CD40). Tethering significantly increased impedance measurement, compared untethered controls. CD19-specific CAR added 24 hours after co-cultured across range ratios. Cytolysis was calculated by comparing treated no treatment control wells. As expected, produced higher cytolysis (54.3%) Raji (70.4%) which express CD19, (30.5%). These results support